The global effort to produce useful anti-Covid medicines is being hampered by the US because researchers are testing drugs in “an arbitrary, willy-nilly way”, the expert leading the UK’s programme has warned.
Britain’s Recovery Trial programme, which has involved 12,000 patients at several hundred British hospitals, has already pinpointed one promising new drug to tackle the disease and also highlighted two others – previously thought to be potential life-savers – as being useless.
But the failure of the US medical system to match this output has meant that other promising treatments that could have been cleared for widespread use have still to be evaluated. In particular, convalescent plasma (blood plasma that is taken from Covid-19 patients and which contains antibodies that could protect others against the disease) has still to be properly tested on a large-scale randomised trial |||READ MORE
No comments:
Post a Comment